{"frequencyBands":{"HP:0040280":[100,100],"HP:0040281":[80,99],"HP:0040282":[30,79],"HP:0040283":[5,29],"HP:0040284":[1,4],"HP:0040285":[0,0]},"page":{"anchorSlug":"neuronal-ceroid-lipofuscinosis-5","columns":[{"countQualifier":"Onset group unspecified","gene":"CLN5","key":"population-3c8fe7ec2cd813ee0c8a","label":"CLN5","mondoId":"MONDO:0009745","onsetQualifier":null,"originColumnKey":"MONDO:0009745","originalViews":[{"key":"MONDO:0009745","label":"CLN5","scopeLabel":"Genetic form","sourceScope":null}],"recordKeys":["040a23cdf814eb5ef200c6b8506a7ceba71fbba391d803c032a23869a1a681ed","055cb70effc66859a16da1b2254d1eb2d540792e26c3d0c7b849e703a8abb56a","0a6f4cdb0ed8b43c4760e6ce8301b89e577e71806a3ee4fd81518d2e2b5fc1a8","181362ff8cc6226c311553ddc1e81ae9bd8d56e69a5481f6466cc9395943660d","280d34a474b03dcb251aeca254d1ffe93ba812aadbaf51e4c923b02e759dd9ca","297fb11cb2ad51ac6015c6d250a9a68578e28a8f7c413c22af39b24e9e43e9be","34721c7ca59456c4459e5e4f8a3182666d4ed03a5a8a21f3e9d9b0bd3e892c57","391f16df01b98d31cd6717be1db67fa73497a8092f6ef2ad6cc6bd3b10d9ecb1","6302e23942ca5823ab9bdc4eabac9615d363386f6f19ec655bdeb39512d00d33","746b723a0464a53ade0eb3cf6d5c93abe116302910f1ead126c1445ac5d58d7f","87bbe3a175e8420a67373ddf3de1182e4acddb6eabb5b82fd260e7a6a75781b5","89dcc693c2e0a2b69be7c57072707b8654cca84d6000e18be81c555d560ae656","8c4ed9c1d346d708ff03832cb7c7e2a289ba65c7a38603320161b14411ae3660","93b849cad7f8a7bbe9726c09b51070624c52ecf07981c679d6e4d598966e89a2","9fa221d6495f3c4f8dc4caf6b4c32735b68ccacb448a46d1b5051d85109430d6","c40e944e3db3927be14df011e0c37dbc95ae861481cdc203c6f45c44eb55eb08","d835e0828a8b34249c09df3e2437242601545dd71ccb5f7111947ab33e8841f1","ddcaf43e84af70302d98bacec308cb9f0e92c99847a8c119fe45ed060573435d","de067dded53cbac50cde01472f9e533cfe18246236a0e1e003fb8513e829be90","e00d8d1818e40b9c85ebd010429615a171e8ced1ae606a08ec0e6009ab3b94a3","e12e35ea855d47ea3c758c84db4fb7ae7f9492429496f215be923f313e4d379f","e6c245364dd0289f3f4c78841ccc5b0b267a2225a4f96b8188c6d238f50cc467","e87a86529e03dad8e651da21b210ac993f7e745f62931266f29a0a06f93b8f86"],"recordQualifiers":{"040a23cdf814eb5ef200c6b8506a7ceba71fbba391d803c032a23869a1a681ed":"Onset group unspecified","391f16df01b98d31cd6717be1db67fa73497a8092f6ef2ad6cc6bd3b10d9ecb1":"Onset group unspecified","6302e23942ca5823ab9bdc4eabac9615d363386f6f19ec655bdeb39512d00d33":"Onset group unspecified","9fa221d6495f3c4f8dc4caf6b4c32735b68ccacb448a46d1b5051d85109430d6":"Onset group unspecified","de067dded53cbac50cde01472f9e533cfe18246236a0e1e003fb8513e829be90":"Onset group unspecified","e12e35ea855d47ea3c758c84db4fb7ae7f9492429496f215be923f313e4d379f":"Onset group unspecified","e6c245364dd0289f3f4c78841ccc5b0b267a2225a4f96b8188c6d238f50cc467":"Onset group unspecified"},"scopeLabel":"Genetic form","sourceIds":["OMIM:256731"],"sourceScope":null}],"comparison":{"collapseColumnsLabel":"Show default populations","defaultColumnKeys":["population-3c8fe7ec2cd813ee0c8a"],"expandColumnsLabel":"Show all source populations","intro":"Features recorded for this MONDO node. Related-node evidence is available through separately scoped comparisons.","primaryFeatureIds":["HP:0001311","HP:0001251","HP:0001272","HP:0002120","HP:0002312","HP:0003205","HP:0002376"],"scopeNoteHtml":"<p>Each column retains its native condition identifier, assessed population and annotation references. Counts are not pooled.</p>"},"coverage":{"countRecords":8,"emptyColumnKeys":[],"hpoRelease":"2026-06-23","narrativeSourceChanges":[],"records":23,"sourceGroups":{"omim":15,"published":8}},"features":[{"hpoId":"HP:0001311","label":"Abnormal nervous system electrophysiology","primary":true},{"hpoId":"HP:0001251","label":"Ataxia","primary":true},{"hpoId":"HP:0001272","label":"Cerebellar atrophy","primary":true},{"hpoId":"HP:0002120","label":"Cerebral cortical atrophy","primary":true},{"hpoId":"HP:0002312","label":"Clumsiness","primary":true},{"hpoId":"HP:0003205","label":"Curvilinear intracellular accumulation of autofluorescent lipopigment storage material","primary":true},{"hpoId":"HP:0002376","label":"Developmental regression","primary":true},{"hpoId":"HP:0001260","label":"Dysarthria","primary":false},{"hpoId":"HP:0002075","label":"Dysdiadochokinesis","primary":false},{"hpoId":"HP:0001310","label":"Dysmetria","primary":false},{"hpoId":"HP:0003208","label":"Fingerprint intracellular accumulation of autofluorescent lipopigment storage material","primary":false},{"hpoId":"HP:0002074","label":"Increased neuronal autofluorescent lipopigment","primary":false},{"hpoId":"HP:0001249","label":"Intellectual disability","primary":false},{"hpoId":"HP:0200085","label":"Limb tremor","primary":false},{"hpoId":"HP:0002505","label":"Loss of ambulation","primary":false},{"hpoId":"HP:0002333","label":"Motor deterioration","primary":false},{"hpoId":"HP:0001336","label":"Myoclonus","primary":false},{"hpoId":"HP:0000639","label":"Nystagmus","primary":false},{"hpoId":"HP:0000529","label":"Progressive visual loss","primary":false},{"hpoId":"HP:0003226","label":"Rectilinear intracellular accumulation of autofluorescent lipopigment storage material","primary":false},{"hpoId":"HP:0000546","label":"Retinal degeneration","primary":false},{"hpoId":"HP:0001250","label":"Seizure","primary":false},{"hpoId":"HP:0001922","label":"Vacuolated lymphocytes","primary":false}],"ledeHtml":"CLN5 disease is an inherited disorder that primarily affects the nervous system. The signs and symptoms of this condition can begin anytime between childhood and early adulthood, but they typically appear around age 5. Children with CLN5 disease often have normal development until they experience the first signs of the condition, which are usually problems with movement that might seem like clumsiness, and a loss of previously acquired motor skills (developmental regression). Other features of the condition include recurrent seizures that involve uncontrollable muscle jerks (myoclonic epilepsy), difficulty coordinating movements (ataxia), vision loss, speech problems, and a decline in intellectual function. The life expectancy of people with CLN5 disease varies; affected individuals usually survive into adolescence or mid-adulthood.","mondoId":"MONDO:0009745","node":{"canonicalSlug":"neuronal-ceroid-lipofuscinosis-5","comparisons":[{"documentSha256":"feab7132c1e6efa19316faa9c5b975a6a6317da700f12b5b4c059a18eda6d069","key":"legacy-cln","kind":"legacy","label":"CLN / Batten disease","memberIds":["MONDO:0008083","MONDO:0008767","MONDO:0008768","MONDO:0008769","MONDO:0009744","MONDO:0009745","MONDO:0010830","MONDO:0011144","MONDO:0012391","MONDO:0012414","MONDO:0012588","MONDO:0012721","MONDO:0013866","MONDO:0014147","MONDO:0016295"],"mondoId":"MONDO:0016295","url":"https://kcjyutqgtpgteszueluf.supabase.co/storage/v1/object/public/community-guides/learn-data/cln.feab7132c1e6efa19316faa9c5b975a6a6317da700f12b5b4c059a18eda6d069.json"},{"documentSha256":"df7e5010cb40de30aba1b0d10ff00b9c8a49865234f6a0ea186c9a1493e9aae3","key":"expanded-cln","kind":"expanded","label":"CLN / Batten disease","memberIds":["MONDO:0008083","MONDO:0008767","MONDO:0008768","MONDO:0008769","MONDO:0009744","MONDO:0009745","MONDO:0010830","MONDO:0011144","MONDO:0012188","MONDO:0012391","MONDO:0012414","MONDO:0012588","MONDO:0012721","MONDO:0013866","MONDO:0014147","MONDO:0016295","MONDO:0017809","MONDO:0019260","MONDO:0019261","MONDO:0019262","MONDO:0030947","MONDO:0850001"],"mondoId":"MONDO:0016295","url":"https://kcjyutqgtpgteszueluf.supabase.co/storage/v1/object/public/community-guides/learn-data/node-comparison-df7e5010cb40de30aba1.df7e5010cb40de30aba1b0d10ff00b9c8a49865234f6a0ea186c9a1493e9aae3.json"}],"contexts":[],"lifecycle":"active","narrative":{"causes":["CLN5 disease is caused by mutations in the CLN5 gene, which provides instructions for making a protein whose function is not well understood. After the CLN5 protein is produced, it is transported to cell compartments called lysosomes, which digest and recycle different types of molecules. Research suggests that the CLN5 protein may play a role in the process by which lysosomes break down or recycle damaged or unneeded proteins within the cell.","Most of the CLN5 gene mutations alter the structure of the protein so that it cannot get to the lysosomes where it is needed. A lack of functional protein within lysosomes probably impairs the breakdown of certain proteins, which then likely accumulate in cells throughout the body. While these accumulations can damage any cells, nerve cells appear to be particularly vulnerable. Widespread loss of nerve cells in CLN5 disease leads to severe signs and symptoms and early death.","In the cases in which CLN5 disease develops in adolescence or adulthood, it is thought that the CLN5 gene mutations lead to a CLN5 protein with reduced function that is broken down earlier than normal. Because the altered CLN5 protein can function for a small amount of time, some damaged or unneeded proteins may be broken down in lysosomes. Since it takes longer for these substances to accumulate and cause nerve cell death, the signs and symptoms of CLN5 disease in these individuals occur later in life."],"causesUrl":"https://medlineplus.gov/genetics/condition/cln5-disease/#causes","contentForm":"summary","matchMethod":"reviewed-binding","name":"CLN5 disease","paragraphs":["CLN5 disease is an inherited disorder that primarily affects the nervous system. The signs and symptoms of this condition can begin anytime between childhood and early adulthood, but they typically appear around age 5. Children with CLN5 disease often have normal development until they experience the first signs of the condition, which are usually problems with movement that might seem like clumsiness, and a loss of previously acquired motor skills (developmental regression). Other features of the condition include recurrent seizures that involve uncontrollable muscle jerks (myoclonic epilepsy), difficulty coordinating movements (ataxia), vision loss, speech problems, and a decline in intellectual function. The life expectancy of people with CLN5 disease varies; affected individuals usually survive into adolescence or mid-adulthood.","CLN5 disease is one of a group of disorders known as neuronal ceroid lipofuscinoses (NCLs), which may also be collectively referred to as Batten disease. All these disorders affect the nervous system and typically cause worsening problems with vision, movement, and thinking ability. The different NCLs are distinguished by their genetic cause. Each disease type is given the designation \"CLN,\" meaning ceroid lipofuscinosis, neuronal, and then a number to indicate its subtype."],"reviewed":"2016-11","scope":"exact","scopeNote":"","source":"MedlinePlus","sourceRelease":"2026-10-01","upstream":"MedlinePlus Genetics","url":"https://medlineplus.gov/genetics/condition/cln5-disease"},"ownColumnKeys":["population-3c8fe7ec2cd813ee0c8a"],"publication":"published","relationships":[{"kind":"parent","label":"late infantile neuronal ceroid lipofuscinosis","mondoId":"MONDO:0015674","slug":"late-infantile-neuronal-ceroid-lipofuscinosis"},{"kind":"parent","label":"neuronal ceroid lipofuscinosis","mondoId":"MONDO:0016295","slug":"cln"}],"schemaVersion":1,"searchIndex":"/node-search/manifest.json","sourceHolds":{},"summaryHolds":[{"reason":"native-cross-reference-does-not-establish-scope","source":"MedlinePlus","url":"https://medlineplus.gov/genetics/condition/cln5-disease"}],"translation":"published","articles":[{"articleId":"rarediseases.info.nih.gov/diseases/1223","pageMondoId":"MONDO:0009745","source":"GARD","name":"Neuronal ceroid lipofuscinosis 5","url":"https://rarediseases.info.nih.gov/diseases/1223","relationToPage":"same-condition","coveredMondoIds":["MONDO:0009745"],"status":"validated-exact-source","presentation":"additional-reference","evidence":["existing-offline-scope-validator","automatic-identity-and-attribution"],"reviewed":null,"sourceRelease":"2026-10-25T03:38:28Z","upstream":"GARD:0001223","rawAttribution":"MONDO:0009745","independentCorroborationEstablished":false}]},"records":[{"frequencyKind":"count","key":"040a23cdf814eb5ef200c6b8506a7ceba71fbba391d803c032a23869a1a681ed","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:256731","disease_name":"Ceroid lipofuscinosis, neuronal, 5","evidence":"PCS","frequency_raw":"2/2","hpo_id":"HP:0001336","is_excluded":false,"label":"Myoclonus","onset_id":null,"reference":"PMID:15728307","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"reported","key":"055cb70effc66859a16da1b2254d1eb2d540792e26c3d0c7b849e703a8abb56a","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:256731","disease_name":"Ceroid lipofuscinosis, neuronal, 5","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0002312","is_excluded":false,"label":"Clumsiness","onset_id":null,"reference":"OMIM:256731","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"range","key":"0a6f4cdb0ed8b43c4760e6ce8301b89e577e71806a3ee4fd81518d2e2b5fc1a8","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:256731","disease_name":"Ceroid lipofuscinosis, neuronal, 5","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0001260","is_excluded":false,"label":"Dysarthria","onset_id":null,"reference":"OMIM:256731","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"reported","key":"181362ff8cc6226c311553ddc1e81ae9bd8d56e69a5481f6466cc9395943660d","raw":{"aspect":"P","body_system":"metabolic","disease_id":"OMIM:256731","disease_name":"Ceroid lipofuscinosis, neuronal, 5","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0003205","is_excluded":false,"label":"Curvilinear intracellular accumulation of autofluorescent lipopigment storage material","onset_id":null,"reference":"OMIM:256731","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"reported","key":"280d34a474b03dcb251aeca254d1ffe93ba812aadbaf51e4c923b02e759dd9ca","raw":{"aspect":"P","body_system":"metabolic","disease_id":"OMIM:256731","disease_name":"Ceroid lipofuscinosis, neuronal, 5","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0003226","is_excluded":false,"label":"Rectilinear intracellular accumulation of autofluorescent lipopigment storage material","onset_id":null,"reference":"OMIM:256731","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"count","key":"297fb11cb2ad51ac6015c6d250a9a68578e28a8f7c413c22af39b24e9e43e9be","raw":{"aspect":"P","body_system":"eye","disease_id":"OMIM:256731","disease_name":"Ceroid lipofuscinosis, neuronal, 5","evidence":"PCS","frequency_raw":"2/2","hpo_id":"HP:0000529","is_excluded":false,"label":"Progressive visual loss","onset_id":"HP:0003621","reference":"PMID:15728307","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"range","key":"34721c7ca59456c4459e5e4f8a3182666d4ed03a5a8a21f3e9d9b0bd3e892c57","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:256731","disease_name":"Ceroid lipofuscinosis, neuronal, 5","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0001310","is_excluded":false,"label":"Dysmetria","onset_id":null,"reference":"OMIM:256731","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"count","key":"391f16df01b98d31cd6717be1db67fa73497a8092f6ef2ad6cc6bd3b10d9ecb1","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:256731","disease_name":"Ceroid lipofuscinosis, neuronal, 5","evidence":"PCS","frequency_raw":"2/2","hpo_id":"HP:0200085","is_excluded":false,"label":"Limb tremor","onset_id":null,"reference":"PMID:15728307","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"count","key":"6302e23942ca5823ab9bdc4eabac9615d363386f6f19ec655bdeb39512d00d33","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:256731","disease_name":"Ceroid lipofuscinosis, neuronal, 5","evidence":"PCS","frequency_raw":"2/2","hpo_id":"HP:0002120","is_excluded":false,"label":"Cerebral cortical atrophy","onset_id":null,"reference":"PMID:15728307","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"range","key":"746b723a0464a53ade0eb3cf6d5c93abe116302910f1ead126c1445ac5d58d7f","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:256731","disease_name":"Ceroid lipofuscinosis, neuronal, 5","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0002075","is_excluded":false,"label":"Dysdiadochokinesis","onset_id":null,"reference":"OMIM:256731","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"range","key":"87bbe3a175e8420a67373ddf3de1182e4acddb6eabb5b82fd260e7a6a75781b5","raw":{"aspect":"P","body_system":"eye","disease_id":"OMIM:256731","disease_name":"Ceroid lipofuscinosis, neuronal, 5","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0000639","is_excluded":false,"label":"Nystagmus","onset_id":null,"reference":"OMIM:256731","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"reported","key":"89dcc693c2e0a2b69be7c57072707b8654cca84d6000e18be81c555d560ae656","raw":{"aspect":"P","body_system":"metabolic","disease_id":"OMIM:256731","disease_name":"Ceroid lipofuscinosis, neuronal, 5","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0003208","is_excluded":false,"label":"Fingerprint intracellular accumulation of autofluorescent lipopigment storage material","onset_id":null,"reference":"OMIM:256731","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"reported","key":"8c4ed9c1d346d708ff03832cb7c7e2a289ba65c7a38603320161b14411ae3660","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:256731","disease_name":"Ceroid lipofuscinosis, neuronal, 5","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0002074","is_excluded":false,"label":"Increased neuronal autofluorescent lipopigment","onset_id":null,"reference":"OMIM:256731","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"reported","key":"93b849cad7f8a7bbe9726c09b51070624c52ecf07981c679d6e4d598966e89a2","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:256731","disease_name":"Ceroid lipofuscinosis, neuronal, 5","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0002333","is_excluded":false,"label":"Motor deterioration","onset_id":null,"reference":"OMIM:256731","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"count","key":"9fa221d6495f3c4f8dc4caf6b4c32735b68ccacb448a46d1b5051d85109430d6","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:256731","disease_name":"Ceroid lipofuscinosis, neuronal, 5","evidence":"PCS","frequency_raw":"2/2","hpo_id":"HP:0001250","is_excluded":false,"label":"Seizure","onset_id":null,"reference":"PMID:15728307","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"reported","key":"c40e944e3db3927be14df011e0c37dbc95ae861481cdc203c6f45c44eb55eb08","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:256731","disease_name":"Ceroid lipofuscinosis, neuronal, 5","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0002376","is_excluded":false,"label":"Developmental regression","onset_id":null,"reference":"OMIM:256731","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"reported","key":"d835e0828a8b34249c09df3e2437242601545dd71ccb5f7111947ab33e8841f1","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:256731","disease_name":"Ceroid lipofuscinosis, neuronal, 5","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0001251","is_excluded":false,"label":"Ataxia","onset_id":null,"reference":"OMIM:256731","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"reported","key":"ddcaf43e84af70302d98bacec308cb9f0e92c99847a8c119fe45ed060573435d","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:256731","disease_name":"Ceroid lipofuscinosis, neuronal, 5","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0001249","is_excluded":false,"label":"Intellectual disability","onset_id":null,"reference":"OMIM:256731","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"count","key":"de067dded53cbac50cde01472f9e533cfe18246236a0e1e003fb8513e829be90","raw":{"aspect":"P","body_system":"blood","disease_id":"OMIM:256731","disease_name":"Ceroid lipofuscinosis, neuronal, 5","evidence":"PCS","frequency_raw":"0/2","hpo_id":"HP:0001922","is_excluded":true,"label":"Vacuolated lymphocytes","onset_id":null,"reference":"PMID:15728307","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"reported","key":"e00d8d1818e40b9c85ebd010429615a171e8ced1ae606a08ec0e6009ab3b94a3","raw":{"aspect":"P","body_system":"eye","disease_id":"OMIM:256731","disease_name":"Ceroid lipofuscinosis, neuronal, 5","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0000546","is_excluded":false,"label":"Retinal degeneration","onset_id":null,"reference":"OMIM:256731","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"count","key":"e12e35ea855d47ea3c758c84db4fb7ae7f9492429496f215be923f313e4d379f","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:256731","disease_name":"Ceroid lipofuscinosis, neuronal, 5","evidence":"PCS","frequency_raw":"2/2","hpo_id":"HP:0001272","is_excluded":false,"label":"Cerebellar atrophy","onset_id":null,"reference":"PMID:15728307","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"count","key":"e6c245364dd0289f3f4c78841ccc5b0b267a2225a4f96b8188c6d238f50cc467","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:256731","disease_name":"Ceroid lipofuscinosis, neuronal, 5","evidence":"PCS","frequency_raw":"2/2","hpo_id":"HP:0002505","is_excluded":false,"label":"Loss of ambulation","onset_id":null,"reference":"PMID:15728307","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"reported","key":"e87a86529e03dad8e651da21b210ac993f7e745f62931266f29a0a06f93b8f86","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:256731","disease_name":"Ceroid lipofuscinosis, neuronal, 5","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0001311","is_excluded":false,"label":"Abnormal nervous system electrophysiology","onset_id":null,"reference":"OMIM:256731","source_release":"2026-06-23"},"sourceGroups":["omim"]}],"referenceLabels":{},"references":{"causeHtml":"<p class=\"section-source\">Source: <a href=\"https://medlineplus.gov/genetics/condition/cln5-disease\" rel=\"noreferrer\">MedlinePlus</a></p><p class=\"section-source\">Source: <a href=\"https://rarediseases.info.nih.gov/diseases/1223\" rel=\"noreferrer\">GARD</a></p><p class=\"section-source\">Source: <a href=\"https://monarchinitiative.org/MONDO:0009745\" rel=\"noreferrer\">MONDO</a></p><details class=\"deep-dive\"><summary>Narrative source and scope</summary><dl><dt>Content</dt><dd>summary</dd><dt>Scope</dt><dd>exact</dd><dt>Match method</dt><dd>reviewed-binding</dd><dt>Upstream attribution</dt><dd>MedlinePlus Genetics</dd></dl></details>","identityNote":"MONDO identifies this node. Native source populations, annotation references and qualified comparison views retain their original scopes.","importantHtml":""},"sections":[{"bodyHtml":"<p>CLN5 disease is an inherited disorder that primarily affects the nervous system. The signs and symptoms of this condition can begin anytime between childhood and early adulthood, but they typically appear around age 5. Children with CLN5 disease often have normal development until they experience the first signs of the condition, which are usually problems with movement that might seem like clumsiness, and a loss of previously acquired motor skills (developmental regression). Other features of the condition include recurrent seizures that involve uncontrollable muscle jerks (myoclonic epilepsy), difficulty coordinating movements (ataxia), vision loss, speech problems, and a decline in intellectual function. The life expectancy of people with CLN5 disease varies; affected individuals usually survive into adolescence or mid-adulthood.</p><p>CLN5 disease is one of a group of disorders known as neuronal ceroid lipofuscinoses (NCLs), which may also be collectively referred to as Batten disease. All these disorders affect the nervous system and typically cause worsening problems with vision, movement, and thinking ability. The different NCLs are distinguished by their genetic cause. Each disease type is given the designation &quot;CLN,&quot; meaning ceroid lipofuscinosis, neuronal, and then a number to indicate its subtype.</p><p class=\"section-source\">Source: <a href=\"https://medlineplus.gov/genetics/condition/cln5-disease\" rel=\"noreferrer\">MedlinePlus</a></p>","key":"overview","title":"Overview"},{"bodyHtml":"<p>CLN5 disease is caused by mutations in the CLN5 gene, which provides instructions for making a protein whose function is not well understood. After the CLN5 protein is produced, it is transported to cell compartments called lysosomes, which digest and recycle different types of molecules. Research suggests that the CLN5 protein may play a role in the process by which lysosomes break down or recycle damaged or unneeded proteins within the cell.</p><p>Most of the CLN5 gene mutations alter the structure of the protein so that it cannot get to the lysosomes where it is needed. A lack of functional protein within lysosomes probably impairs the breakdown of certain proteins, which then likely accumulate in cells throughout the body. While these accumulations can damage any cells, nerve cells appear to be particularly vulnerable. Widespread loss of nerve cells in CLN5 disease leads to severe signs and symptoms and early death.</p><p>In the cases in which CLN5 disease develops in adolescence or adulthood, it is thought that the CLN5 gene mutations lead to a CLN5 protein with reduced function that is broken down earlier than normal. Because the altered CLN5 protein can function for a small amount of time, some damaged or unneeded proteins may be broken down in lysosomes. Since it takes longer for these substances to accumulate and cause nerve cell death, the signs and symptoms of CLN5 disease in these individuals occur later in life.</p><p class=\"section-source\">Source: <a href=\"https://medlineplus.gov/genetics/condition/cln5-disease/#causes\" rel=\"noreferrer\">MedlinePlus</a></p>","key":"causes","title":"Causes"}],"sharedSources":[],"slug":"neuronal-ceroid-lipofuscinosis-5","sourceDocuments":[{"name":"MedlinePlus: CLN5 disease","reviewed":"2016-11","source_release":"2026-10-01","url":"https://medlineplus.gov/genetics/condition/cln5-disease"},{"name":"GARD: Neuronal ceroid lipofuscinosis 5","reviewed":null,"source_release":"2026-10-25T03:38:28Z","url":"https://rarediseases.info.nih.gov/diseases/1223"},{"name":"MONDO: neuronal ceroid lipofuscinosis 5","reviewed":null,"source_release":"releases/2026-10-06","url":"https://monarchinitiative.org/MONDO:0009745"}],"sourceNote":"","synonyms":["ceroid lipofuscinosis, neuronal, 5","ceroid lipofuscinosis, neuronal, type 5","CLN5","CLN5 disease, adult","CLN5 disease, juvenile","CLN5 disease, late infantile (subtype)","CLN5 neuronal ceroid lipofuscinosis","neuronal ceroid lipofuscinosis caused by mutation in CLN5","neuronal ceroid lipofuscinosis Finnish variant","neuronal ceroid lipofuscinosis type 5"],"takeawayHtml":"","title":"neuronal ceroid lipofuscinosis 5"},"schemaVersion":1}
